Aaron Guanliang Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Aaron Guanliang Lim has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Peter Vickerman
University of Bristol
12 shared publications - Josephine G. Walker
Bristol Medical School, University of Bristol
6 shared publications - Matthew Hickman
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
5 shared publications Peter Vickerman
Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
4 shared publicationsAdam Trickey
Population Health Sciences, Bristol Medical School University of Bristol Bristol UK
3 shared publications- Adam Trickey
University of Bristol
3 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (9) , e70219
Prevalence of Hepatitis B Virus Infection in Cameroon: A Systematic Review and Meta‐Analysis
Chronic hepatitis B virus (HBV) infection is a global public health problem, and many regions of Sub‐Saharan Africa are disproportionately affected, including Cameroon, where prevalence has previously been shown to be high. This study aimed to provide up‐to‐date estimates of HBV prevalence in Cameroon. We searched Medline, Global Health, Embase, Web of Science, Cochrane Library, Africa Index Medicus and the Journal of Health Science and Disease at the University of Yaounde. We included studies reporting HBV surface antigen (HBsAg) prevalence in the general population and subpopulations. A random‐effects meta‐analysis was used to generate pooled estimates of HBsAg prevalence, overall and for population subgroups including those considered at relatively higher‐risk and relatively lower‐risk of HBV infection. Heterogeneity was assessed using the index of heterogeneity ( I 2 ). Quality was assessed using the Joanna Briggs Institute critical appraisal tool. Out of 1236 records, 92 papers with 100 studies were included in the meta‐analysis. Overall prevalence of HBV in Cameroon was 9.98% (95% confidence interval [CI] 9.00–11.02) with high heterogeneity ( I 2 = 98.10% ) . The prevalences for relatively lower‐risk and higher‐risk populations were8.94% (95% CI 7.84–10.11) and 12.70% (95% CI 10.28–15.32), respectively. In subgroup analyses, we found that sex, geographical area (regions), population risk groups and study design were the main sources of heterogeneity. Overall, HBV prevalence remains high in Cameroon. Our findings suggest an urgent need for health interventions to halt the spread of the disease, with particular attention needed for males and regions with the highest prevalence.
- 5 August 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (9) , e70219
Open AccessPrevalence of Hepatitis B Virus Infection in Cameroon: A Systematic Review and Meta‐Analysis
Chronic hepatitis B virus (HBV) infection is a global public health problem, and many regions of Sub‐Saharan Africa are disproportionately affected, including Cameroon, where prevalence has previously been shown to be high. This study aimed to provide up‐to‐date estimates of HBV prevalence in Cameroon. We searched Medline, Global Health, Embase, Web of Science, Cochrane Library, Africa Index Medicus and the Journal of Health Science and Disease at the University of Yaounde. We included studies reporting HBV surface antigen (HBsAg) prevalence in the general population and subpopulations. A random‐effects meta‐analysis was used to generate pooled estimates of HBsAg prevalence, overall and for population subgroups including those considered at relatively higher‐risk and relatively lower‐risk of HBV infection. Heterogeneity was assessed using the index of heterogeneity ( I 2 ). Quality was assessed using the Joanna Briggs Institute critical appraisal tool. Out of 1236 records, 92 papers with 100 studies were included in the meta‐analysis. Overall prevalence of HBV in Cameroon was 9.98% (95% confidence interval [CI] 9.00–11.02) with high heterogeneity ( I 2 = 98.10% ) . The prevalences for relatively lower‐risk and higher‐risk populations were8.94% (95% CI 7.84–10.11) and 12.70% (95% CI 10.28–15.32), respectively. In subgroup analyses, we found that sex, geographical area (regions), population risk groups and study design were the main sources of heterogeneity. Overall, HBV prevalence remains high in Cameroon. Our findings suggest an urgent need for health interventions to halt the spread of the disease, with particular attention needed for males and regions with the highest prevalence.
- Open Access
- 10 April 2026
- Published by Taylor & Francis in Global Public Health
- Vol. 21 (1) , 2654240
Seroprevalence of hepatitis C virus among refugees, asylum seekers, and internally displaced populations within Africa: A systematic review and meta-analysis
Hepatitis C virus (HCV), an often overlooked public health concern, is highly prevalent among marginalized groups. Refugees, asylum seekers, and internally displaced people (RASIDP) constitute an underserved population in healthcare. Given that displacement rates are increasing and that HCV is endemic to many African countries, we aimed to determine the prevalence of HCV among RASIDP communities in Africa. Studies investigating HCV prevalence within RASIDP communities across Africa were identified via the following database searches: Ovid MEDLINE, EMBASE, Web of Science, APA PsycINFO, and the WHO Africa Index Medicus. Seroprevalence estimates were meta-analysed using a random-effects model, with data stratified by participant region, age, and gender. Across 9 studies, we estimated a pooled HCV seroprevalence of 3.63% (95% CI: 0.54, 9.16) among RASIDP in Africa. Seroprevalence varied by region of origin and age, with those from Northern Africa and those aged > 40 years having the highest seroprevalence, at 10.03% (95% CI:9.03, 11.13) and 5.70% (95% CI: 0.81, 14.21), respectively. RASIDP communities represent a marginalised and vulnerable population that often faces significant barriers to accessing healthcare. Our findings show that HCV seroprevalence within these communities varies by region and age, thus suggesting a need for targeted screening approaches.
- 10 April 2026
- Published by Taylor & Francis in Global Public Health
- Vol. 21 (1) , 2654240
Open AccessSeroprevalence of hepatitis C virus among refugees, asylum seekers, and internally displaced populations within Africa: A systematic review and meta-analysis
Hepatitis C virus (HCV), an often overlooked public health concern, is highly prevalent among marginalized groups. Refugees, asylum seekers, and internally displaced people (RASIDP) constitute an underserved population in healthcare. Given that displacement rates are increasing and that HCV is endemic to many African countries, we aimed to determine the prevalence of HCV among RASIDP communities in Africa. Studies investigating HCV prevalence within RASIDP communities across Africa were identified via the following database searches: Ovid MEDLINE, EMBASE, Web of Science, APA PsycINFO, and the WHO Africa Index Medicus. Seroprevalence estimates were meta-analysed using a random-effects model, with data stratified by participant region, age, and gender. Across 9 studies, we estimated a pooled HCV seroprevalence of 3.63% (95% CI: 0.54, 9.16) among RASIDP in Africa. Seroprevalence varied by region of origin and age, with those from Northern Africa and those aged > 40 years having the highest seroprevalence, at 10.03% (95% CI:9.03, 11.13) and 5.70% (95% CI: 0.81, 14.21), respectively. RASIDP communities represent a marginalised and vulnerable population that often faces significant barriers to accessing healthcare. Our findings show that HCV seroprevalence within these communities varies by region and age, thus suggesting a need for targeted screening approaches.
- Open Access
- 12 March 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (4) , e70164
Delivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan
Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan. Data on patients ( n = 1288, median age 40 years) initiating direct‐acting antiviral (DAA) treatment (October 2016 to December 2018) were extracted from hospital records. Eligible patients had chronic HCV, were treatment naïve, and without hepatic decompensation. Multivariable logistic regression analysed factors associated with treatment outcomes (not completing treatment, treatment completion without sustained virological response test at 12 weeks (SVR12) visit, and treatment completion with SVR12). Costs (2019 USD) were estimated using micro‐costing from financial records and staff interviews. Among 1288 patients (63% women), 93% (1200/1288) completed treatment, and 74% (884/1200) attended SVR12 visit, with 98% ( n = 870/884) cured. Compared with 0–29 year‐olds, incomplete treatment was lower among 30–49 year‐olds (aOR 0.47 [0.26–0.83]) and ≥ 50 year‐olds (aOR 0.48 [0.24–0.93]). SVR12 non‐attendance was higher for 24‐week versus 12‐week regimens (aOR: 3.46 [1.51–7.93]), but lower for patients with APRI scores 0.5–1.49 (aOR 0.69 [0.50–0.96]) and ≥ 1.5 (aOR 0.44 [0.24–0.78]) compared to 0–0.49. The mean treatment cost was $370.74 per patient, driven by clinic visits $271.80 (73.3%), labs $68.32 (18.4%), and DAAs $30.62 (8.3%). Overall, a high treatment completion and cure rate were achieved, with a low average cost per patient, indicating that this HCV treatment model can be affordable and may be considered for widescale treatment scale‐up in Pakistan.
- 12 March 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (4) , e70164
Open AccessDelivering Effective Hepatitis C Virus Treatment in an Embedded Primary Care Setting Within a Tertiary Care Hospital in Karachi, Pakistan
Hepatitis C virus (HCV) endemic regions require accessible treatment interventions. Effectiveness and costs of a pilot HCV treatment programme were evaluated at an embedded primary care service within a tertiary care centre at Indus Hospital and Health Network in Karachi, Pakistan. Data on patients ( n = 1288, median age 40 years) initiating direct‐acting antiviral (DAA) treatment (October 2016 to December 2018) were extracted from hospital records. Eligible patients had chronic HCV, were treatment naïve, and without hepatic decompensation. Multivariable logistic regression analysed factors associated with treatment outcomes (not completing treatment, treatment completion without sustained virological response test at 12 weeks (SVR12) visit, and treatment completion with SVR12). Costs (2019 USD) were estimated using micro‐costing from financial records and staff interviews. Among 1288 patients (63% women), 93% (1200/1288) completed treatment, and 74% (884/1200) attended SVR12 visit, with 98% ( n = 870/884) cured. Compared with 0–29 year‐olds, incomplete treatment was lower among 30–49 year‐olds (aOR 0.47 [0.26–0.83]) and ≥ 50 year‐olds (aOR 0.48 [0.24–0.93]). SVR12 non‐attendance was higher for 24‐week versus 12‐week regimens (aOR: 3.46 [1.51–7.93]), but lower for patients with APRI scores 0.5–1.49 (aOR 0.69 [0.50–0.96]) and ≥ 1.5 (aOR 0.44 [0.24–0.78]) compared to 0–0.49. The mean treatment cost was $370.74 per patient, driven by clinic visits $271.80 (73.3%), labs $68.32 (18.4%), and DAAs $30.62 (8.3%). Overall, a high treatment completion and cure rate were achieved, with a low average cost per patient, indicating that this HCV treatment model can be affordable and may be considered for widescale treatment scale‐up in Pakistan.
- Open Access
- 13 December 2025
- Published by Oxford University Press (OUP) in International Health
- Vol. 18 (5) , 758-766
Coverage and determinants of hepatitis B virus vaccine uptake among children aged 12–36 months in Ethiopia: an analysis of the 2016 Ethiopian Demographic and Health Survey
Background: In Ethiopia, chronic hepatitis B virus (HBV) prevalence is high (∼6%) and infant vaccination targets are unmet. We assessed HBV vaccination uptake and associations with parental sociodemographic and obstetric factors among children (aged 12–36 months) in Ethiopia. Methods: We utilised the 2016 Ethiopian Demographic and Health Survey. We included a weighted sample of 3,855 children (aged 12–36 month) to assess HBV vaccination coverage level (none, incomplete, and complete) and its spatial distribution. Additionally, we identified associated factors of HBV vaccination coverage level using ordinal logistic regression. Results: Overall, 51.2% of children received complete HBV vaccination, with wide regional variation. Older maternal age (adjusted odds ratio (AOR)=1.05, 95% confidence interval (CI): 1.02–1.07), better maternal education level (mean AOR=1.66–2.08), higher household wealth quantile (mean AOR=1.51–2.32), distance to a healthcare facility not a big problem (AOR=1.54, 95% CI: 1.25–1.89), and complete maternal continuum care utilisation (AOR=2.59, 95% CI: 1.25–5.30) were positively associated with HBV vaccination coverage, while higher number of children in the household (AOR=0.86, 95% CI: 0.79–0.92) was negatively associated. Conclusions: HBV vaccination coverage falls below World Health Organization (WHO) targets in Ethiopia and has substantial regional variation. Targeted vaccination campaigns for mothers in lower socioeconomic groups and larger families may improve vaccination coverage.
- 13 December 2025
- Published by Oxford University Press (OUP) in International Health
- Vol. 18 (5) , 758-766
Open AccessCoverage and determinants of hepatitis B virus vaccine uptake among children aged 12–36 months in Ethiopia: an analysis of the 2016 Ethiopian Demographic and Health Survey
Background: In Ethiopia, chronic hepatitis B virus (HBV) prevalence is high (∼6%) and infant vaccination targets are unmet. We assessed HBV vaccination uptake and associations with parental sociodemographic and obstetric factors among children (aged 12–36 months) in Ethiopia. Methods: We utilised the 2016 Ethiopian Demographic and Health Survey. We included a weighted sample of 3,855 children (aged 12–36 month) to assess HBV vaccination coverage level (none, incomplete, and complete) and its spatial distribution. Additionally, we identified associated factors of HBV vaccination coverage level using ordinal logistic regression. Results: Overall, 51.2% of children received complete HBV vaccination, with wide regional variation. Older maternal age (adjusted odds ratio (AOR)=1.05, 95% confidence interval (CI): 1.02–1.07), better maternal education level (mean AOR=1.66–2.08), higher household wealth quantile (mean AOR=1.51–2.32), distance to a healthcare facility not a big problem (AOR=1.54, 95% CI: 1.25–1.89), and complete maternal continuum care utilisation (AOR=2.59, 95% CI: 1.25–5.30) were positively associated with HBV vaccination coverage, while higher number of children in the household (AOR=0.86, 95% CI: 0.79–0.92) was negatively associated. Conclusions: HBV vaccination coverage falls below World Health Organization (WHO) targets in Ethiopia and has substantial regional variation. Targeted vaccination campaigns for mothers in lower socioeconomic groups and larger families may improve vaccination coverage.
- Open Access
- 8 July 2025
- Vol. 5 (7) , e0004706
Hepatitis C virus cascade of care among adults in Sindh province, Pakistan: Findings from 2019-2020 household sero-survey.
Pakistan has the largest national burden of hepatitis C virus (HCV) infections (9.8 million). High levels of testing and treatment are needed to achieve HCV elimination, but little data exists on this in Pakistan. A household sero-survey from Sindh province (2019-2020) collected self-reported data from adults on previous HCV testing and treatment, and undertook HCV-antibody (HCV-Ab) testing of participants (2988 children (25 years), and adults with a secondary or higher education level were more likely to have ever been tested for HCV, as were individuals with a family history of hepatitis, received HBV vaccination or that had various risk factors linked to HCV transmission (e.g., blood transfusion, having tattoo/acupuncture, hospitalisation or therapeutic injection (s) history). The cascade-of-care for HCV needs improving to eliminate HCV in Pakistan, especially among younger adults, women and people with low education levels.
- 8 July 2025
- Vol. 5 (7) , e0004706
Open AccessHepatitis C virus cascade of care among adults in Sindh province, Pakistan: Findings from 2019-2020 household sero-survey.
Pakistan has the largest national burden of hepatitis C virus (HCV) infections (9.8 million). High levels of testing and treatment are needed to achieve HCV elimination, but little data exists on this in Pakistan. A household sero-survey from Sindh province (2019-2020) collected self-reported data from adults on previous HCV testing and treatment, and undertook HCV-antibody (HCV-Ab) testing of participants (2988 children (25 years), and adults with a secondary or higher education level were more likely to have ever been tested for HCV, as were individuals with a family history of hepatitis, received HBV vaccination or that had various risk factors linked to HCV transmission (e.g., blood transfusion, having tattoo/acupuncture, hospitalisation or therapeutic injection (s) history). The cascade-of-care for HCV needs improving to eliminate HCV in Pakistan, especially among younger adults, women and people with low education levels.
- Open Access
- 1 April 2025
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (2) , 394-408
Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
Background/Aims: The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.Methods: Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths.Results: The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868).Conclusions: Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.
- 1 April 2025
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 31 (2) , 394-408
Open AccessCost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study
Background/Aims: The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.Methods: Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths.Results: The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868).Conclusions: Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.
- Open Access
- 13 September 2024
- Published by Wiley in Liver International
- Vol. 44 (12) , 3238-3249
Prevalence, trends, and distribution of hepatitis C virus among the general population in sub‐Saharan Africa: A systematic review and meta‐analysis
Background and Aims: Although the evidence is uncertain, existing estimates for hepatitis C virus (HCV) in sub‐Saharan Africa (SSA) indicate a high burden. We estimated HCV seroprevalence and viraemic prevalence among the general population in SSA.Methods: We searched Medline, Embase, Web of Science, APA PsycINFO, and World Health Organization Africa Index Medicus for community‐based studies. Study quality was assessed using the Joanna Briggs Institute critical appraisal tool, and heterogeneity using the index of heterogeneity (I2). Two approaches were deployed. First, we used random‐effects meta‐analysis to pool prevalence. Second, to derive representative estimates, we weighted each country's HCV seroprevalence using 2021 United Nations country population sizes.Results: We synthesized 130 studies. Overall, SSA HCV seroprevalence from the random‐effects model was 4.17% (95% confidence interval [CI]: 3.71–4.66, I2 = 99.30%). There were no differences between males (4.31%) and females (4.03%). Seroprevalence was 2.25%, 3.31%, and 16.23% for ages ≤20, 21–64, and ≥65 years, respectively, and was higher in rural (6.63%) versus urban (2.93%). There was indication of decrement overtime from 5.74% to 4.35% to 3.03% in the years 1984–2000, 2001–2014, and 2015–2023, respectively. The weighted overall SSA HCV seroprevalence was estimated to be 2.30% (95% CI: 1.59–3.00) with regional variation: Africa‐Southern (.79%), Africa‐Central (1.47%), Africa‐Eastern (2.71%), and Africa‐Western (2.88%). HCV viremia among HCV seropositives was 54.77% (95% CI: 47.80–61.66).Conclusions: HCV seroprevalence in SSA remains high. Populations aged ≥65 years, rural communities, Africa‐Western, and some countries in Africa‐Central and Africa‐Eastern appear disproportionately affected. These results underline the need for governmental commitment to achieve the 2030 global HCV elimination targets.
- 13 September 2024
- Published by Wiley in Liver International
- Vol. 44 (12) , 3238-3249
Open AccessPrevalence, trends, and distribution of hepatitis C virus among the general population in sub‐Saharan Africa: A systematic review and meta‐analysis
Background and Aims: Although the evidence is uncertain, existing estimates for hepatitis C virus (HCV) in sub‐Saharan Africa (SSA) indicate a high burden. We estimated HCV seroprevalence and viraemic prevalence among the general population in SSA.Methods: We searched Medline, Embase, Web of Science, APA PsycINFO, and World Health Organization Africa Index Medicus for community‐based studies. Study quality was assessed using the Joanna Briggs Institute critical appraisal tool, and heterogeneity using the index of heterogeneity (I2). Two approaches were deployed. First, we used random‐effects meta‐analysis to pool prevalence. Second, to derive representative estimates, we weighted each country's HCV seroprevalence using 2021 United Nations country population sizes.Results: We synthesized 130 studies. Overall, SSA HCV seroprevalence from the random‐effects model was 4.17% (95% confidence interval [CI]: 3.71–4.66, I2 = 99.30%). There were no differences between males (4.31%) and females (4.03%). Seroprevalence was 2.25%, 3.31%, and 16.23% for ages ≤20, 21–64, and ≥65 years, respectively, and was higher in rural (6.63%) versus urban (2.93%). There was indication of decrement overtime from 5.74% to 4.35% to 3.03% in the years 1984–2000, 2001–2014, and 2015–2023, respectively. The weighted overall SSA HCV seroprevalence was estimated to be 2.30% (95% CI: 1.59–3.00) with regional variation: Africa‐Southern (.79%), Africa‐Central (1.47%), Africa‐Eastern (2.71%), and Africa‐Western (2.88%). HCV viremia among HCV seropositives was 54.77% (95% CI: 47.80–61.66).Conclusions: HCV seroprevalence in SSA remains high. Populations aged ≥65 years, rural communities, Africa‐Western, and some countries in Africa‐Central and Africa‐Eastern appear disproportionately affected. These results underline the need for governmental commitment to achieve the 2030 global HCV elimination targets.
- 2 September 2024
- Published by Springer Nature in PharmacoEconomics
- Vol. 42 (12) , 1345-1357
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
Background and Objective China has the highest number of hepatitis C virus (HCV) infections in the world. However, it is unclear what levels of screening and treatment are needed to achieve the WHO 2030 hepatitis C elimination targets. We aimed to evaluate the impact of scaling up interventions on the hepatitis C epidemic and determine how and at what cost these elimination targets could be achieved for the whole population in China. Methods We developed a compartmental model incorporating HCV transmission, disease progression, and care cascade for the whole population in China, calibrated with data on demographics, injecting drug use, HCV prevalence, and treatments. Five different scenarios were evaluated for effects and costs for 2022–2030. All costs were converted to 2021 US dollar (USD) and discounted at an annual rate of 5%. One-way sensitivity analyses were conducted to assess the robustness of the model. Results Under the status quo scenario, the incidence of hepatitis C is projected to increase from 60.39 (57.60–63.45) per 100,000 person-years in 2022 to 68.72 (65.3–73.97) per 100,000 person-years in 2030, and 2.52 million (1.94–3.07 million) infected patients are projected to die between 2022 and 2030, of which 0.76 (0.61–1.08) million will die due to hepatitis C. By increasing primary screening to 10%, conducting regular rescreening (annually for PWID and every 5 years for the general population) and treating 90% of patients diagnosed, the incidence would be reduced by 88.15% (86.61–89.45%) and hepatitis C-related mortality by 60.5% (52.62–65.54%) by 2030, compared with 2015 levels. This strategy would cost USD 52.78 (USD 43.93–58.53) billion. Conclusions Without changes in HCV prevention and control policy, the disease burden of HCV in China will increase dramatically. To achieve the hepatitis C elimination targets, China needs to sufficiently scale up screening and treatment.
- 2 September 2024
- Published by Springer Nature in PharmacoEconomics
- Vol. 42 (12) , 1345-1357
Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study
Background and Objective China has the highest number of hepatitis C virus (HCV) infections in the world. However, it is unclear what levels of screening and treatment are needed to achieve the WHO 2030 hepatitis C elimination targets. We aimed to evaluate the impact of scaling up interventions on the hepatitis C epidemic and determine how and at what cost these elimination targets could be achieved for the whole population in China. Methods We developed a compartmental model incorporating HCV transmission, disease progression, and care cascade for the whole population in China, calibrated with data on demographics, injecting drug use, HCV prevalence, and treatments. Five different scenarios were evaluated for effects and costs for 2022–2030. All costs were converted to 2021 US dollar (USD) and discounted at an annual rate of 5%. One-way sensitivity analyses were conducted to assess the robustness of the model. Results Under the status quo scenario, the incidence of hepatitis C is projected to increase from 60.39 (57.60–63.45) per 100,000 person-years in 2022 to 68.72 (65.3–73.97) per 100,000 person-years in 2030, and 2.52 million (1.94–3.07 million) infected patients are projected to die between 2022 and 2030, of which 0.76 (0.61–1.08) million will die due to hepatitis C. By increasing primary screening to 10%, conducting regular rescreening (annually for PWID and every 5 years for the general population) and treating 90% of patients diagnosed, the incidence would be reduced by 88.15% (86.61–89.45%) and hepatitis C-related mortality by 60.5% (52.62–65.54%) by 2030, compared with 2015 levels. This strategy would cost USD 52.78 (USD 43.93–58.53) billion. Conclusions Without changes in HCV prevention and control policy, the disease burden of HCV in China will increase dramatically. To achieve the hepatitis C elimination targets, China needs to sufficiently scale up screening and treatment.
- Open Access
Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial
Background and aims: The INTRO‐HCV randomized controlled trial conducted in Norway over 2017–2019 found that integrated treatment, compared with standard‐of‐care hospital treatment, for hepatitis C virus (HCV) with direct‐acting antivirals (DAAs) improved treatment outcomes among people who inject drugs (PWID). We evaluated cost‐effectiveness of the INTRO‐HCV intervention.Design: A Markov health state transition model of HCV disease progression and treatment with cost‐effectiveness analysis from the health‐provider perspective. Primary cost, utility, and health outcome data were derived from the trial. Costs and health benefits (quality‐adjusted life‐years, QALYs) were tracked over 50 years. Probabilistic and univariate sensitivity analyses investigated DAA price reductions and variations in HCV treatment and disease care cost assumptions, using costs from different countries (Norway, United Kingdom, United States, France, Australia).Setting and participants: PWID attending community‐based drug treatment centers for people with opioid dependence in Norway.Measurements: Incremental cost‐effectiveness ratio (ICER) in terms of cost per QALY gained, compared against a conventional (€70 000/QALY) willingness‐to‐pay threshold for Norway and lower (€20 000/QALY) threshold common among high‐income countries.Findings: Integrated treatment resulted in an ICER of €13 300/QALY gained, with 99% and 71% probability of being cost‐effective against conventional and lower willingness‐to‐pay thresholds, respectively. A 30% lower DAA price reduced the ICER to €6 900/QALY gained, with 91% probability of being cost‐effective at the lower willingness‐to‐pay threshold. A 60% and 90% lower DAA price had 36% and >99% probability of being cost‐saving, respectively. Sensitivity analyses suggest integrated treatment was cost‐effective at the lower willingness‐to‐pay threshold (>60% probability) across different assumptions on HCV treatment and disease care costs with 30% DAA price reduction, and became cost‐saving with 60%–90% price reductions.Conclusions: Integrated hepatitis C virus treatment for people who inject drugs in community settings is likely cost‐effective compared with standard‐of‐care referral pathways in Norway and may be cost‐saving in settings with particular characteristics.
Open AccessCost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial
Background and aims: The INTRO‐HCV randomized controlled trial conducted in Norway over 2017–2019 found that integrated treatment, compared with standard‐of‐care hospital treatment, for hepatitis C virus (HCV) with direct‐acting antivirals (DAAs) improved treatment outcomes among people who inject drugs (PWID). We evaluated cost‐effectiveness of the INTRO‐HCV intervention.Design: A Markov health state transition model of HCV disease progression and treatment with cost‐effectiveness analysis from the health‐provider perspective. Primary cost, utility, and health outcome data were derived from the trial. Costs and health benefits (quality‐adjusted life‐years, QALYs) were tracked over 50 years. Probabilistic and univariate sensitivity analyses investigated DAA price reductions and variations in HCV treatment and disease care cost assumptions, using costs from different countries (Norway, United Kingdom, United States, France, Australia).Setting and participants: PWID attending community‐based drug treatment centers for people with opioid dependence in Norway.Measurements: Incremental cost‐effectiveness ratio (ICER) in terms of cost per QALY gained, compared against a conventional (€70 000/QALY) willingness‐to‐pay threshold for Norway and lower (€20 000/QALY) threshold common among high‐income countries.Findings: Integrated treatment resulted in an ICER of €13 300/QALY gained, with 99% and 71% probability of being cost‐effective against conventional and lower willingness‐to‐pay thresholds, respectively. A 30% lower DAA price reduced the ICER to €6 900/QALY gained, with 91% probability of being cost‐effective at the lower willingness‐to‐pay threshold. A 60% and 90% lower DAA price had 36% and >99% probability of being cost‐saving, respectively. Sensitivity analyses suggest integrated treatment was cost‐effective at the lower willingness‐to‐pay threshold (>60% probability) across different assumptions on HCV treatment and disease care costs with 30% DAA price reduction, and became cost‐saving with 60%–90% price reductions.Conclusions: Integrated hepatitis C virus treatment for people who inject drugs in community settings is likely cost‐effective compared with standard‐of‐care referral pathways in Norway and may be cost‐saving in settings with particular characteristics.